Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ovid Therapeutics (OVID) Other Non Operating Income (2022 - 2025)

Historic Other Non Operating Income for Ovid Therapeutics (OVID) over the last 4 years, with Q3 2025 value amounting to $365000.0.

  • Ovid Therapeutics' Other Non Operating Income rose 14679.49% to $365000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $4.5 million, marking a year-over-year decrease of 8768.45%. This contributed to the annual value of $35.5 million for FY2024, which is 41061.5% up from last year.
  • Latest data reveals that Ovid Therapeutics reported Other Non Operating Income of $365000.0 as of Q3 2025, which was up 14679.49% from $389000.0 recorded in Q2 2025.
  • In the past 5 years, Ovid Therapeutics' Other Non Operating Income ranged from a high of $29.0 million in Q2 2024 and a low of -$780000.0 during Q3 2024
  • For the 4-year period, Ovid Therapeutics' Other Non Operating Income averaged around $3.1 million, with its median value being $836085.0 (2022).
  • The largest annual percentage gain for Ovid Therapeutics' Other Non Operating Income in the last 5 years was 154614.51% (2024), contrasted with its biggest fall of 20051.55% (2024).
  • Ovid Therapeutics' Other Non Operating Income (Quarter) stood at $668123.0 in 2022, then soared by 329.11% to $2.9 million in 2023, then plummeted by 48.76% to $1.5 million in 2024, then tumbled by 75.15% to $365000.0 in 2025.
  • Its last three reported values are $365000.0 in Q3 2025, $389000.0 for Q2 2025, and $2.3 million during Q1 2025.